Actively hiring
Science & Engineering
Biotechnology
Health Care
As featured in
Follow
Overview
News
Salaries
Products
People
Growth
Offices
Financials
Funding and backers
Total raised
$81.8M
2 rounds on record
Latest round
$40.9M
Venture round · Aug 2022 · 4 yr ago
Team
14
US Form 5500 (plan participants) · Dec 2025 · -7% in a year
Backers
1
ARCH Venture Partners
The money's age
Long since its last round
49 months since the last round · not hiring
Momentum
15/100
in the news
Last sign of life
this month
a posting or a news item
The story so fareach stage dated by its source: the company's releases, the press, registers, filings
Aug 8, 2022
Raised a round Venture round $40.9M · SEC Form D
Aug 8, 2022
Raised a round Venture round $40.9M · SEC Form D
2021
Founded
Funding rounds
| Round | Date | Amount | Investors | Source |
|---|---|---|---|---|
| Venture round | Aug 2022 | $40.9M | — | SEC Form D |
| Venture round | Aug 2022 | $40.9M | — | SEC Form D |
Registers and programsofficial lists and records that name the company
| Legal entity | Skylark Bio, Inc. | SEC Form D |
Founders and leadersfrom filings, registers and the company's site
Nilay ThakarExecutive Officer, DirectorSEC Form D
Jodi CookExecutive Officer, DirectorSEC Form D
Will McLeanExecutive OfficerSEC Form D
Backed byfrom the funds' portfolios and accelerator catalogs
Investors in similar startupsfunds that back the companies most like this one
Similar startupsby what they do, their industry and backers

Our Science Platform Pipeline REM-422 About Us Our Story Our People Our Investors Our Partners Join Us News News Presentations Press…

ABOUT US PRODUCTS PRESS CONTACT US ABOUT US PRODUCTS PRESS CONTACT US MacroCycle is not building belief. We are engineering inevitability.

At Jaguar Gene Therapy, we believe in a world where patients and families won’t have to hear those words. Our mission is to accelerate…

Home Our Company Capabilities Products Contact Us About Us News Capabilities Certificates Aramid UD UHMWPE UD Chopped Carbon Fiber Home Our…

Linus Health is revolutionizing brain health with trusted, science-driven solutions; supporting earlier detection, intervention, and…

GoMo Health delivers a behavioral science-driven engagement solutions that improve outcomes and scales care across healthcare organizations.
News
Skylark Bio lance un essai de thérapie génique pour la surdité liée au gène GJB2
Une nouvelle étape vient d'être franchie dans le développement des thérapiesgéniques appliquées à la surdité. La société américaine Skylark Bio annonce avoiradministré pour la première fois son candidat SKY-GJB2 à un patient atteint d'unesurdité génétique
Read more
Report
Gene therapy trial for most common genetic cause of inherited paediatric deafness Hearing Practitioner News August 15, 2026
Read more
Report
Skylark trials gene therapy for common form of child deafness
Skylark Bio dosed the first patient in a phase 1/2 trial of SKY-GJB2, a gene therapy for the most common form of genetic deafness in children.
Read more
Report
Report
First patient in Skylark Bio's Phase I/II trial receives SKY-GJB2 gene therapy
Skylark Bio has dosed the first patient in its SONIX Phase I/II clinical trial assessing SKY-GJB2 as a potential gene therapy for children with hearing loss linked to GJB2 gene changes.
Read more
Report
ASGCT 2026: Skylark Bio is developing a gene therapy for the largest cause of pediatric deafness. They have plans to be in the clinic this summer and early data will come by the end of the year
President & CEO Jodi Cook describes how Skylark is targeting the GJB2 gene, and the work that has went into delivering the gene therapy to the right cells in the inner ear and only those cell.
Read more
Report
People

Nilay Thakar
Executive Officer, Director

Jodi Cook
Executive Officer, Director

Will McLean
Executive Officer

Giampiero De Luca
Director

Steve Gillis
Director
Names and roles come from public filings, company registers and the company's own site. Is this you? Correct or remove · How we handle this data
Offices
Where the company hires and what each office is for
Cities
1
Hiring now
0
Countries
1
Cambridge
United States
HQ
50-200 est. staff

ARCH Venture Partners 




